|本期目录/Table of Contents|

[1]丁皓月,王毓佳综述,泥艳红审校.肌腱蛋白在肿瘤中作用的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2019,21(02):167-170.[doi:10.3969/j.issn.1672-271X.2019.02.012]
　DING Hao-yue,WANG Yu-jia reviewing,NI Yan-hong checking.Research progress in the role of TNC in tumor[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(02):167-170.[doi:10.3969/j.issn.1672-271X.2019.02.012]
点击复制

肌腱蛋白在肿瘤中作用的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第21卷
期数:
2019年02期
页码:
167-170
栏目:
综述
出版日期:
2019-03-20

文章信息/Info

Title:
Research progress in the role of TNC in tumor
作者:
丁皓月; 王毓佳综述; 泥艳红审校
作者单位：210008 南京，南京大学医学院附属口腔医院（南京市口腔医院）口腔颌面外科（丁皓月）,中心试验室（王毓佳，泥艳红）
Author(s):
DING Hao-yue1;  WANG Yu-jia2 reviewing ;  NI Yan-hong1 checking
（1.Department of Oral and Maxillofacial Surgery, 2.Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing 210008, Jiangsu, China）
关键词:
肌腱蛋白; 细胞外基质糖蛋白; 肿瘤细胞; 肿瘤间质
Keywords:
Tenascin-c;  extracellular matrix glycoprotein;  tumor cells;  tumor stroma
分类号:
R73
DOI:
10.3969/j.issn.1672-271X.2019.02.012
文献标志码:
A
摘要:
肌腱蛋白（TNC）是一种细胞外基质糖蛋白，在胚胎发育和器官形成过程中高度表达，正常成人组织不表达。但在大多数肿瘤细胞和细胞外间质中TNC表达增高，参与肿瘤细胞增殖、黏附和迁移、肿瘤血管生成及肿瘤免疫等。文章主要就TNC在促进肿瘤发生发展中作用等方面进行综述。
Abstract:
Tenascin-C (TNC) is an extracellular matrix glycoprotein that disappears in normal tissues after embryonic development, but is highly expressed in inflammation, tissue damage, and tumors. At present, attention has been paid to the role of TNC in tumor progression. This article will review the role of TNC in promoting tumorigenesis, growth, and metastasis, as well as the diagnosis, treatment, and prognosis of tumors.

参考文献/References:

[1] Bourdon MA, Wikstrand CJ, Furthmayr H ,et al. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody[J]. Cancer Res, 1983, 43(6): 2796-2805.
[2] 农云宏，白浪. Tenascin-C促进肿瘤转移的分子机制研究进展[J].生物医学工程学杂志，2015，32（1）：240-244.
[3] Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis[J]. J Cell Commun Signal, 2009, 3(3-4): 287-310.
[4] Yoshida T, Akatsuka T, Imanaka-Yoshida K. Tenascin-C and integrins in cancer[J]. Cell Adh Migr, 2015, 9(1-2): 96-104.
[5] Wiese S, Faissner A. The role of extracellular matrix in spinal cord development[J]. Exp Neurol, 2015, 274(Pt B): 90-99.
[6] Fluck M, Tunc-Civelek V, Chiquet M. Rapid and reciprocal regulation of tenascin-C and tenascin-Y expression by loading of skeletal muscle[J]. J Cell Sci, 2000, 113(Pt 20)：3583-3591.
[7] Mori M, Muramatsu Y, Yamada K ,et al. Intracellular localization of tenascin in squamous cell carcinoma of oral cavity: an immunohistochemical study[J]. Anticancer Res, 1996, 16(5B): 3075-3079.
[8] Chiquet-Ehrismann R, Kalla P, Pearson CA. Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts[J]. Cancer Res, 1989, 49(15): 4322-4325.
[9] Adams M, Jones JL, Walker RA ,et al. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease[J]. Cancer Res, 2002, 62(11): 3289-3297.
[10] Hancox RA, Allen MD, Holliday DL ,et al. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms[J]. Breast Cancer Res, 2009, 11(2): R24.
[11] Pedretti M, Soltermann A, Arni S ,et al. Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer[J]. Lung cancer, 2009, 64(1): 28-33.
[12] Ishiwata T, Takahashi K, Shimanuki Y ,et al. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer[J]. Anticancer Res, 2005, 25(1B): 489-495.
[13] Xia S, Lal B, Tung B ,et al. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation[J]. Neuro Oncol, 2016, 18(4): 507-517.
[14] Mackie EJ, Chiquet-Ehrismann R, Pearson CA ,et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland[J]. Proc Natl Acad Sci USA, 1987, 84(13): 4621-4625.
[15] Jahkola T, Toivonen T, von Smitten K ,et al. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis[J]. Int J Cancer, 1996, 69(6): 445-447.
[16] Yang ZT, Yeo SY, Yin YX ,et al. Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma[J]. PLoS One, 2016, 11(1): e0145807.
[17] Ni WD, Yang ZT, Cui CA ,et al. Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer[J]. Biochem Biophys Res Commun, 2017, 486(3): 607-612.
[18] Gecks T, Junker K, Franz M ,et al. B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder?[J]. Clin Chim Acta, 2011, 412(21-22): 1931-1936.
[19] 左衍海，施鑫. 恶性肿瘤转移机制研究新进展[J]. 医学研究生学报，2008，21(3) : 293-297.
[20] Huang W, Chiquet-Ehrismann R, Moyano JV ,et al. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation[J]. Cancer Res, 2001, 61(23): 8586-8594.
[21] Fischer D, Tucker RP, Chiquet-Ehrismann R,et al. Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes[J]. Mol Biol Cell, 1997, 8(10): 2055-2075.
[22] Katoh D, Nagaharu K, Shimojo N ,et al. Binding of alphavbeta1 and alphavbeta6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells[J]. Oncogenesis, 2013, 2(8)：e65.
[23] Tanaka K, Hiraiwa N, Hashimoto H,et al. Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression[J]. Int J Cancer, 2004, 108(1): 31-40.
[24] Kawakatsu H, Shiurba R, Obara M ,et al. Human carcinoma cells synthesize and secrete tenascin in vitro[J]. Jpn J Cancer Res, 1992,83(10):1073-1080.
[25] Fukunaga-Kalabis M, Martinez G, Nguyen TK ,et al. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population[J]. Oncogene, 2010, 29(46): 6115-6124.
[26] Van Obberghen-Schilling E, Tucker RP, Saupe F ,et al. Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth[J]. Int J Dev Biol, 2011, 55(4-5): 511-525.
[27] Saupe F, Schwenzer A, Jia Y ,et al. Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model[J]. Cell Rep, 2013, 5(2): 482-492.
[28] Puente Navazo MD, Valmori D, Ruegg C. The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production[J]. J Immunol, 2001, 167(11): 6431-6440.
[29] Parekh K, Ramachandran S, Cooper J ,et al. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes[J]. Lung cancer, 2005, 47(1): 17-29.
[30] Hauzenberger D, Olivier P, Gundersen D ,et al. Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin[J]. Eur J Immunol, 1999, 29(5): 1435-1447.
[31] Gong XG, Lv YF, Li XQ ,et al. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells[J]. Biol Pharm Bull, 2010, 33(8): 1261-1267.
[32] 黄迎娣，崔蕾，黄利鸣，等. 上皮间质转化与肿瘤耐药[J]. 东南国防医药，2014，16(6): 624-628.
[33] 胡翰青，刘蔚，马行健，等. P53蛋白、VEGF和CD34在涎腺腺样囊性癌中的表达及意义[J]. 东南国防医药，2013，15(6): 592-593.

相似文献/References:

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81772880）
更新日期/Last Update: 2019-03-20